Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View DetailsGuangzhou, China/Bad Vilbel, Germany –Bio-Thera will maintainresponsibility for development, manufacturing, and supply of the tocilizumabbiosimilar to Roche’s RoActemra® reference brand. STADA, including its affiliates, will have exclusive rights to ...
Guangzhou – July 16, 2025 – Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of biosimilars and innovative todayannounced that the U.S. Food and Drug Administration (FDA) has accepted itsBiologic...
Guangzhou,China – July 2025 – Bio-Thera Solutions, Inc. (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosimilars, today announced that the Independent Data Monitoring Committee(IDMC) has re...
